Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study
Tommaso Giarratano(Istituto Oncologico Veneto), Maria Vittoria Dieci(University of Padua), Federica Miglietta(University of Padua), Elisabetta Di Liso(Istituti di Ricovero e Cura a Carattere Scientifico), Grazia Maria Vernaci(University of Padua), Giulia Tasca(University of Padua), M. Zanocco(Istituto Oncologico Veneto), Valentina Guarneri(Istituto Oncologico Veneto), Alice Menichetti(University of Padua), Giovanni Faggioni(Istituto Oncologico Veneto), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Mara Mantiero(University of Padua), Gaia Griguolo(University of North Carolina at Chapel Hill), Daniela de Mattos Grosso(Istituto Oncologico Veneto), Simona Frezzini(Istituti di Ricovero e Cura a Carattere Scientifico), Cristina Falci(Istituti di Ricovero e Cura a Carattere Scientifico), Eleonora Mioranza(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 25
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226